Oramed Pharmaceuticals (ORMP)

Oramed’s most prominent candidate has been ORMD-0801, an oral insulin capsule developed for diabetes. The product is intended to offer a more convenient alternative to injectable insulin by delivering insulin through the portal vein, a route that may more closely resemble natural physiology. The company has also explored ORMD-0801 for nonalcoholic steatohepatitis, commonly known as NASH, a liver disease associated with metabolic dysfunction. Another programme, ORMD-0901, is based on oral delivery of GLP-1, a class of therapies used in metabolic disease.

The company operates in a high-risk, research-driven segment of the healthcare market. Its value depends heavily on clinical trial outcomes, regulatory progress, intellectual property, partnerships, and the ability to finance development through lengthy approval processes. Oral biologic delivery is a potentially large opportunity because it could improve patient adherence and broaden the use of important therapies, but it is technically difficult and subject to rigorous testing.

For investors, Oramed represents exposure to a specialised drug-delivery platform rather than a diversified pharmaceutical business. Its prospects are tied to whether its technology can demonstrate safety, efficacy, and commercial viability in major metabolic disease indications.